SPY345.03+3.02 0.88%
DIA284.38+2.35 0.83%
IXIC11,567.44+88.56 0.77%

Citigroup Downgrades Eidos Therapeutics to Neutral, Lowers Price Target to $73.26

Citigroup analyst Joel Beatty downgrades Eidos Therapeutics (NASDAQ:EIDX) from Buy to Neutral and lowers the price target from $80 to $73.26.

· 10/07/2020 09:02
Citigroup analyst Joel Beatty downgrades Eidos Therapeutics (NASDAQ:EIDX) from Buy to Neutral and lowers the price target from $80 to $73.26.